No Data
No Data
Express News | Arrivent Biopharma Inc Files for Mixed Shelf; Size Not Disclosed - SEC Filing
Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket
ArriVent BioPharma's Strategic Licensing and Partnerships Position It for Growth in ADC Development
ArriVent BioPharma Analyst Ratings
H.C. Wainwright Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Raises Target Price to $39
ArriVent BioPharma's Strategic Expansion and Promising Clinical Results Justify Buy Rating and Increased Price Target